{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:17:42Z","timestamp":1792059462663,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula). Notably, neovascular, or wet, AMD (nAMD) occurs when new, abnormal blood vessels grow under the macula causing scarring of the macula itself and resulting in a loss of central vision, visual distortion, and an impaired capacity of perceiving colour contrast and intensity. Brolucizumab, a new generation anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, was approved by the European Medicines Agency for the treatment of nAMD. The aim of this analysis is to evaluate the cost-effectiveness profile of brolucizumab, compared to the main therapeutic alternative available (aflibercept), for the treatment of nAMD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The simulation of costs and outcomes was carried out using a Markov model over a time horizon of 15\u2009years. In base-case, treatment effectiveness inputs for brolucizumab and aflibercept were extracted from the HAWK and HARRIER studies and from a network meta-analysis. The Italian National Healthcare Service (NHS) perspective was considered, therefore only healthcare direct costs (treatment acquisition, administration, adverse events, disease monitoring) were analysed. In the alternative scenarios, the societal perspective and a prolonged time horizon were considered. Model robustness was tested through sensitivity analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the base-case analysis, brolucizumab was dominant over aflibercept (+\u20090.11\u2009years QALY gained and -\u20ac15,679 costs). Both one-way deterministic and probabilistic sensitivity analyses confirmed the robustness and reliability of base-case results. The results of the probabilistic sensitivity analysis showed that when the willingness to pay is equal to \u20ac50,000 per QALY gained, brolucizumab would be dominant in 84% of simulations and in the remaining simulations brolucizumab would be cost-effective compared to aflibercept. Results of the alternative scenarios and sensitivity analyses confirmed the results of base-case.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The cost-utility analysis shows that brolucizumab is dominant over aflibercept. Treatment with brolucizumab reduces the economic impact of nAMD and determined a slight increase of quality-adjusted survival. This analysis gives a high level of confidence that the treatment with brolucizumab would reduce the burden of intravitreal injections, compared to aflibercept, a relevant therapeutic alternative in Italy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-07972-w","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:05:13Z","timestamp":1651187113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy"],"prefix":"10.1186","volume":"22","author":[{"given":"Nicola","family":"Ferrante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ritrovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Bitonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Furneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"7972_CR1","unstructured":"American Academy of Ophtalmology. What Is Macular Degeneration? [Internet]. Available: https:\/\/www.aao.org\/eye-health\/diseases\/amd-macular-degeneration"},{"key":"7972_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archopht.118.1.47","volume":"118","author":"GC Brown","year":"2000","unstructured":"Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118:47\u201351. https:\/\/doi.org\/10.1001\/archopht.118.1.47.","journal-title":"Arch Ophthalmol"},{"key":"7972_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archopht.116.4.514","volume":"116","author":"RA Williams","year":"1998","unstructured":"Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmo. 1998;116:514\u201320. https:\/\/doi.org\/10.1001\/archopht.116.4.514.","journal-title":"Arch Ophthalmo"},{"key":"7972_CR4","doi-asserted-by":"publisher","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035.","DOI":"10.1016\/j.ophtha.2017.05.035"},{"key":"7972_CR5","doi-asserted-by":"publisher","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012:1728\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(12)60282-7.","DOI":"10.1016\/S0140-6736(12)60282-7"},{"key":"7972_CR6","doi-asserted-by":"publisher","unstructured":"Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration. a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115. https:\/\/doi.org\/10.1016\/j.ophtha.2007.03.008.","DOI":"10.1016\/j.ophtha.2007.03.008"},{"key":"7972_CR7","doi-asserted-by":"publisher","unstructured":"Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS one. Public library of. Science. 2014;9. https:\/\/doi.org\/10.1371\/journal.pone.0101072.","DOI":"10.1371\/journal.pone.0101072"},{"key":"7972_CR8","unstructured":"LEGGE 23 dicembre 1996, n. 648. (GU n.300 del 23-12-1996). Available: https:\/\/www.normattiva.it\/uri-res\/N2Ls?urn:nir:stato:legge:1996-12-23;648!vig=."},{"key":"7972_CR9","doi-asserted-by":"publisher","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti\u2013vascular endothelial growth factor therapy of macular diseases [internet]. Graefe\u2019s Arch Clin Exp Ophthalmol. 2017:1259\u201373. https:\/\/doi.org\/10.1007\/s00417-017-3647-4.","DOI":"10.1007\/s00417-017-3647-4"},{"key":"7972_CR10","doi-asserted-by":"publisher","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for Neovascular age-related macular degeneration. Ophthalmology. 2019. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"7972_CR11","unstructured":"National Institute for Health and Care Excellence (2013b) [TA409] single technology appraisal: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. Disponibile: https:\/\/www.nice.org.uk\/guidance\/TA409\/doc."},{"key":"7972_CR12","unstructured":"National Institute for Health and Care Excellence (2010) [TA229] Dexamethasone intravitreal implant (Ozurdex\u00ae) for the treatment of macular oedema caused by retinal vein occlusion - Single technology appraisal (STA), Disponibile: https:\/\/www.nice.org.uk\/g."},{"key":"7972_CR13","unstructured":"ClinicalTrials.gov (2015) Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 - Identifier: NCT02434328. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02434328."},{"key":"7972_CR14","unstructured":"ClinicalTrials.gov (2014) Efficacy and Safety of RTH258 Versus Aflibercept - Identifier: NCT02307682. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02307682."},{"key":"7972_CR15","doi-asserted-by":"publisher","unstructured":"Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: Report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014. https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.026.","DOI":"10.1016\/j.ophtha.2014.04.026"},{"key":"7972_CR16","volume-title":"Brolucizumab for the treatment of adults with neovascular (WET) age-related macular degeneration (AMD)","author":"European Network for Health Technology Assessment (EUnetHTA)","year":"2020","unstructured":"European Network for Health Technology Assessment (EUnetHTA). Brolucizumab for the treatment of adults with neovascular (WET) age-related macular degeneration (AMD). 2020 [Internet]. Available: https:\/\/www.eunethta.eu\/wp-content\/uploads\/2020\/03\/PTJA09-brolucizumab-final-assessment-report-v1.0.pdf"},{"key":"7972_CR17","doi-asserted-by":"publisher","unstructured":"Hodgson R, Reason T, Trueman D, Wickstead R, Kusel J, Jasilek A, et al. Challenges associated with estimating utility in wet age-related macular degeneration: a novel regression analysis to capture the bilateral nature of the disease. Adv Ther. 2017. https:\/\/doi.org\/10.1007\/s12325-017-0620-x.","DOI":"10.1007\/s12325-017-0620-x"},{"key":"7972_CR18","unstructured":"Istituto nazionale di statistica (ISTAT). Tavole di mortalit\u00e0 della popolazione residente, 2019. Disponibile al sito: http:\/\/demo.istat.it\/tvm2016\/index.php?lingua=ita."},{"key":"7972_CR19","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1167\/IOVS.08-1676","volume":"49","author":"S Christ","year":"2008","unstructured":"Christ S, Lee D, Lam B, Zheng D, Arheart K. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Invest Ophthalmol Vis Sci. Invest Ophthalmol Vis Sci. 2008;49:3318\u201323. https:\/\/doi.org\/10.1167\/IOVS.08-1676.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7972_CR20","unstructured":"National Institute for Health and Care Excellence (2018a) Age-related macular degeneration - NICE guideline [N82] https:\/\/www.nice.org.uk\/guidance\/ng82\/."},{"key":"7972_CR21","unstructured":"National Institute for Health and Care Excellence (2018b) Age-related macular degeneration - NICE guideline [N82] Appendix J: Health economics. https:\/\/www.nice.org.uk\/guidance\/ng82\/evidence\/appendix-j-health-economics-pdf-170036251093."},{"key":"7972_CR22","doi-asserted-by":"publisher","unstructured":"Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for Subfoveal Neovascular macular degeneration. Ophthalmology. 2007. https:\/\/doi.org\/10.1016\/j.ophtha.2006.09.019.","DOI":"10.1016\/j.ophtha.2006.09.019"},{"key":"7972_CR23","unstructured":"Agenzia Italiana del Farmaco (AIFA). Rinegoziazione del medicinale per uso umano \u00abEylea\u00bb. GU Serie Generale n.235 del 07-10-2019. Available at: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2019\/10\/07\/19A06166\/SG."},{"key":"7972_CR24","unstructured":"Agenzia Italiana del Farmaco (AIFA). Riclassificazione del medicinale per uso umano \u00abBeovu\u00bb. GU n.323 del 31-12-2020. Available at: https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_DG-1342-2020_Beovu.pdf\/d72658d0-b32f-ee36-bd55-18f47424f6c7."},{"key":"7972_CR25","unstructured":"Novartis. Report. Gestione delle prestazioni relative alla somministrazione intravitreale di farmaci. Ottobre. 2019. Data on file."},{"key":"7972_CR26","unstructured":"Muscio A, Ciriaci D, Cruciani F. A simulation of cost-benefit analysis of blindness prevention in Italy. Clin Ter. 2011;162(6):e187\u201394."},{"key":"7972_CR27","unstructured":"Italian Ministry of Health. Rates of hospital services. Supplement n. 8, Official Gazette n. 23, 2013. Attachment 1. Available at: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=28\/01\/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001."},{"key":"7972_CR28","unstructured":"Ministero della salute. Tariffe delle prestazioni ambulatoriali. GU n. 23, 2013. http:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=45074&completo=true."},{"key":"7972_CR29","unstructured":"National Observatory on the Use of Medicines (OsMed). The use of medicines in Italy. Raporto Nazionale Anno 2019. [Internet]. Available: https:\/\/www.aifa.gov.it\/documents\/20142\/1205984\/rapporto-osmed-2019.pdf"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-07972-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:06:02Z","timestamp":1651187162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-07972-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7972"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-07972-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"24 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Furneri G. and Bitonti R.: consulting fees from Novartis Farma S.p.A. for analysis conduction.Ferrante N. and Ritrovato D.: employees of Novartis Farma S.p.A.No further CoI were declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"573"}}